Table 2.
Occurrence of treatments at any time during the observation period.
| National population1)(n=811) | Regional population1)(n=127) | |||
|---|---|---|---|---|
| n (%) | 95% CI | n (%) | 95% CI | |
| Any treatment | 714 (88.0%) | 85.6-90.2 | 126 (99.2%) | 95.7-100.0 |
| Surgery | ||||
| Any surgery | 584 (72.0%) | 68.8-75.1 | 112 (88.2%) | 81.3-93.2 |
| Primary site | 542 (66.8%) | 63.5-70.1 | 105 (82.7%) | 75.0-88.8 |
| Gall or bile ducts | 143 (17.6%) | 15.1-20.4 | 58 (45.7%) | 36.8-54.7 |
| Lymph nodes | 97 (12.0%) | 9.8-14.4 | 47 (37.0%) | 28.6-46.0 |
| Liver | 81 (10.0%) | 8.0-12.3 | 11 (8.7%) | 4.4-15.0 |
| Peritoneum | 22 (2.7%) | 1.7-4.1 | 12 (9.4%) | 5.0-15.9 |
| Other | 10 (1.2%) | 0.6-2.3 | n<5 | n<5 |
| Locoregional interventions | ||||
| HAE | 80 (9.9%) | 7.9-12.1 | 40 (31.5%) | 23.5-40.3 |
| RFA | 75 (9.2%) | 7.3-11.5 | 9 (7.1%) | 3.3-13.0 |
| PRRT | 66 (8.1%) | 6.3-10.2 | 11 (8.7%) | 4.4-15.0 |
| Pharmacological treatment | ||||
| SSA | 470 (58.0%) | 54.5-61.4 | 95 (74.8%) | 66.3-82.1 |
| IFN-alpha | 148 (18.2%) | 15.6-21.1 | 22 (17.3%) | 11.2-25.0 |
| Chemotherapy | 93 (11.5%) | 9.4-13.9 | 13 (10.2%) | 5.6-16.9 |
| Molecular targeted therapy | 24 (3.0%) | 1.9-4.4 | 6 (4.7%) | 1.8-10.0 |
HAE: hepatic artery embolization; IFN: interferon; PRRT: peptide receptor radionuclide therapy; RFA: radiofrequency ablation; SSA: somatostatin analogues.
Footnote:
1) The Regional population is a subgroup of the National population; hence, the National population and the Regional population should not be compared.